PharmaCyte Biotech, Inc. PMCB · Stock Open PharmaCyte Biotech, Inc. in new tab
PharmaCyte Biotech, Inc. Analysis (PMCB)
Is PharmaCyte Biotech, Inc. a good investment? PharmaCyte Biotech, Inc. (PMCB) is currently trading at 0.7610 USD.
In terms of valuation, the stock trades at a P/E ratio of 16.50. This valuation is generally in line with the broader market.
Earnings Schedule: PharmaCyte Biotech, Inc. is expected to release its next earnings report on July 1, 2026. The market consensus estimate for Forward EPS is -0.38.
Investor FAQ
Does PharmaCyte Biotech, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is PharmaCyte Biotech, Inc.?
PharmaCyte Biotech, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 1, 2026. The company currently has a trailing EPS of -0.89.
Company Profile
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Split Date | Split Ratio to 1 |
|---|---|
| July 12, 2021 | 0.000000 |
Community Discussion